Investor Presentation on the Financial Results of the Company for the quarter and year ended March 31, 2026
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Neuland Laboratories reported exceptional Q4FY26 results with Total Income of Rs. 788.7 crore (up 134.9% YoY), EBITDA of Rs. 319.4 crore (up 448.6% YoY), and PAT of Rs. 212.5 crore (up 666.3% YoY). For FY26, Total Income reached Rs. 2,053.1 crore (37.1% YoY growth) with EBITDA of Rs. 603.4 crore (76% YoY) and PAT of Rs. 363.1 crore (40% YoY). EBITDA margin expanded significantly from 17.3% in Q4FY25 to 40.5% in Q4FY26, and from 22.9% in FY25 to 29.4% in FY26. The company maintained a net cash position with Net Debt at Rs. (156.8) crore. CMS (Custom Manufacturing Solutions) business drove growth through commercial molecules and new project orders. Prime segment molecules Ezetimibe and Mirtazapine performed well. Capex outflow was Rs. 397 crore in FY26 with new peptide manufacturing facility and R&D centre on track.
Strong margin expansion and operating leverage signal operational efficiency improvements. The net cash position and robust order pipeline from CMS business provide financial stability. Revenue growth of 37.1% YoY with EBITDA margin improvement of 650 bps indicates sustained profitability, which is positive for shareholders.